Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of ARSI on PSMA PET in mCRPC
NCT04279561Phase 1Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Apr 2020
- Primary completion
- Sep 2022
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium ga-68 gozetotide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Changes in 68Ga-PSMA-11 lesion and total-body uptake (SUVmax and SUVmean) at 1 year. Started Apr 2020; status: terminated.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04279561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04279561.